Yaohong Liu, Wensou Huang, Mingji He, Hui Lian, Yongjian Guo, Jingjun Huang, Jingwen Zhou, Kangshun Zhu
Oncology Research, Vol.27, No.5, pp. 565-573, 2019, DOI:10.3727/096504018X15313896322888
Abstract This study aimed to investigate the efficacy and safety of drug-eluting beads transarterial chemoembolization
(DEB-TACE) treatment in Barcelona Clinic Liver Cancer (BCLC) stage C liver cancer patients. In 39 patients
with BCLC stage C liver cancer, after the first cycle of DEB-TACE, 2 (5.1%) and 24 (61.5%) patients achieved
complete response (CR) and partial response (PR) to give an overall objective response rate (ORR) of 66.7%.
With respect to the second cycle of therapy, the ORR was higher in patients receiving DEB-TACE compared
with those receiving cTACE (57.1% vs. 11.1%). After the first cycle of DEB-TACE treatment, the percentages
of… More >
Login
Register
